for references). Stockholm, Sweden PlGF is exclusively a ligand for VEGFR-1 (Park et al., 5 Corresponding author 1994). VEGFR-1 and VEGFR-2 have seven immunoglobulin (Ig)-like loops in the extracellular domain (EC), The recently identified vascular endothelial growth a single transmembrane region and a tyrosine kinase factor C (VEGF-C) belongs to the platelet-derived domain, interrupted by an insert of 60-70 amno acid growth factor (PDGF)/VEGF family of growth factors residues (de Vries et al., 1992; Terman et al., 1992 ; and is a ligand for the endothelial-specific receptor Shibuya, 1995) . tyrosine kinases VEGFR-3 and VEGFR-2. The VEGF Three novel growth factors strikingly similar to VEGF homology domain spans only about one-third of the and PlGF have been identified recently. These factors cysteine-rich VEGF-C precursor. Here we have are the VEGF-B/VEGF-related factor (VRF) (Grimmond analysed the role of post-translational processing Olofsson et al., 1996a) , VEGF-C/VEGF-VEGF-C secretion and function, as well as the structure related protein (VRP) Lee et al. , of the mature VEGF-C. The stepwise proteolytic pro-1996) and c-fos-induced growth factor (FIGF) (Orlandini cessing of VEGF-C generated several VEGF-C forms et al., 1996) . VEGF-B is most closely related to VEGF with increased activity towards VEGFR-3, but only and is able to form heterodimers with it (Olofsson et al. , the fully processed VEGF-C could activate VEGFR-2.
1996a,b). VEGF-C and FIGF are similar in that both have Recombinant 'mature' VEGF-C made in yeast bound N-and C-terminal extensions flanking a VEGF homology VEGFR-3 (K D ⍧ 135 pM) and VEGFR-2 (K D ⍧ 410 domain. Their C-terminal propeptides contain tandemly pM) and activated these receptors. Like VEGF, mature repeated motifs with a spacing of cysteine residues typical VEGF-C increased vascular permeability, as well as of Balbiani ring 3 protein (BR3P) ; the migration and proliferation of endothelial cells.
Introduction expressed in angioblasts of the head mesenchyme and in the veins of embryos, and selectively in lymphatic endoAngiogenesis, the formation of blood vessels by sprouting thelia thereafter . The paracrine from pre-existing ones, is regulated by a balance between expression patterns of VEGF-C and VEGFR-3 in many positive and negative regulators (Hanahan and Folkman, tissues suggest that VEGF-C may function in angiogenesis 1996). Vascular endothelial growth factor (VEGF) belongs of the lymphatic vasculature  Kukk to the platelet-derived growth factor (PDGF) /VEGF family et al., 1996) . On the other hand, the ability of VEGF-C and is a major inducer of angiogenesis in normal and to activate VEGFR-2 points to its possible functional pathological conditions (Dvorak et al., 1995; Carmeliet redundancy with VEGF. et al., 1996; Ferrara et al., 1996; Ferrara, 1997) . The
The VEGF-C precursor is more than twice as large as biological effects of VEGF are largely specific for endothe mature polypeptide, initially isolated from PC-3 cell thelial cells and include stimulation of their proliferation, culture media . This, combined with migration and tube formation, and regulation of vascular permeability (Dvorak et al., 1995; Klagsbrun and the unusual structure of the precursor, raised questions about the role of its proteolytic processing, possibly affecting receptor specificity, affinity and biological activity. These questions have been addressed in the present study.
Results

Characterization of VEGF-C antibodies and mapping of peptide epitopes in reduced and alkylated VEGF-C polypeptides
To study VEGF-C processing, we first generated antisera recognizing two different regions of the VEGF-C precursor. Antiserum 882 was obtained by immunization with a synthetic peptide corresponding to amino acid residues 2-18 of the N-terminus of mature secreted human VEGF-C [residues 104-120 of the VEGF-C prepropeptide ; EMBL, GenBank and DDBJ entry X94216]. Antiserum 905 was raised against the N-terminus of the putative VEGF-C propeptide (residues 33-54) (see Figure 3 ). These antisera and the extracellular domain of VEGFR-3 (R-3EC) were then compared for their ability to bind metabolically labelled recombinant VEGF-C from the conditioned media (CM) of transfected 293-EBNA cells. Both antibodies precipitated VEGF-C forms with molecular masses of 15, 21, as well as a doublet of 29/31 kDa ( Figure 1A , lanes 3 and 5, arrows). At higher levels of VEGF-C expression, polypeptides of 43 and 58 kDa were also detected in the immunoprecipitates ( Figures 1B and 2 ). Importantly, both antibodies immunoprecipitated the VEGF-C forms which were able to bind (Figure 1A , lanes 4 and 6), indicating that they were 3, 5 and 7) or from CM treated with dithiothreitol and iodoacetamide specific for VEGF-C.
to reduce and alkylate disulfide bonds (lanes 2, 4, 6 and 8).
In order to explore the structure of the VEGF-C peptides further, we compared the abilities of the antisera to bind other hand, the 21, 29 and 43 kDa forms were not affected VEGF-C after reduction and alkylation of disulfide bonds.
by the R102S mutation, suggesting that these polypeptides This treatment prevented the precipitation of the 29 and contain peptide sequences located C-terminally of R102. 43 kDa polypeptides by both antisera and of the 21 kDa
The specificity of antiserum 905 was demonstrated further form by antiserum 905 ( Figure 1B, lanes 1-4) . Reduction by its inability to immunoprecipitate a VEGF-C mutant and alkylation slowed down the migration of the VEGFin which the N-terminal propeptide (residues 32-102) was C polypeptides in SDS-PAGE, presumably by dissociating deleted (∆N, see Figures 1B and 3) . The ∆N polypeptide, intrachain bonds. Therefore, the absence of the 29 kDa immunoprecipitated with the 882 antiserum, migrated in form in these conditions could have been due to its co-SDS-PAGE with a mobility corresponding to the size of migration with the 31 kDa component of the doublet. To the deletion (~8 kDa) and it was co-precipitated with an show that this is not the case, we generated an artificial equal amount of another pair of polypeptides of N-glycosylation site in the N-terminal part of VEGF-C by 29-32 kDa, which were not recognized by antiserum replacing Arg102 with a serine residue, resulting in the 882 upon reduction/alkylation of disulfide bonds. These NSS(102) peptide (see Figure 3 ). This mutation slowed polypeptides were considered to represent heterogenously down the mobility of the polypeptide normally migrating cleaved/glycosylated C-terminal fragments of the ∆N at 31 kDa and therefore improved the separation of the precursor. doublet, thus confirming the above conclusion (data not shown). The mobilities of the 58 and 15 kDa forms were Biosynthesis, dimerization and proteolytic also reduced to 64 and 21 kDa respectively, indicating processing of VEGF-C that these VEGF-C polypeptides contained the appropriate To analyse the kinetics of VEGF-C biosynthesis and processing, we performed metabolic pulse-chase labelling N-terminal peptide of VEGF-C (data not shown). On the (compare lanes 15Ј-2 h run in reducing and non-reducing conditions). At later chase times, these complexes were cleaved further, with concominant accumulation of a 15 and a 21 kDa polypeptide in reducing conditions (lanes 2-24 h). Importantly, this step of the processing occurs after secretion, as no 15 or 21 kDa forms were detected in the cell lysates (upper panels).
To analyse the composition of the different secreted VEGF-C forms we separated 35 S-labelled recombinant VEGF-C polypeptides by SDS-PAGE in non-reducing conditions, excised the polypeptide bands from the gel, reduced the disulfide bonds by treatment of the gel pieces with β-mercaptoethanol and re-analysed the polypeptides in reducing conditions ( Figure 2B ). The major part of the high molecular weight VEGF-C forms (bands 1-3) gave rise to 29/31 kDa doublets, confirming that the cleaved VEGF-C polypeptides are disulfide-bonded. Only a small fraction of the precursor protein is non-processed or partially processed (products of 58 and 43 kDa in the right hand panel). The low molecular weight components (lanes 4 and 5) contain heterodimerized 15, 21, 29 and 31 kDa polypeptides as well as homodimers of the 31 kDa polypeptide. Interestingly, the monomeric 21 kDa form was also detected (lane 6). The 15 kDa product was disulfide bonded only with the 29 kDa polypeptide (lane 4).
Identification of the proteolytically processed and disulfide-linked forms of VEGF-C
We next used the purified IgG fraction of antiserum 882 to isolate recombinant VEGF-C by affinity chromatography as described in Materials and methods. The purified material contained major polypeptides of 15, 21, 29-30 and 31-32 kDa (data not shown). These polypeptides latter polypeptide revealed the N-terminal amino acid sequence NH 2 -S(228)LPATL-COOH.
Comparison of the obtained sequences with the sequence experiments with cells expressing recombinant VEGF-C. Analysis of the immunoprecipitated VEGF-C polypeptides of the VEGF-C precursor indicated that polypeptides of 15 and 31 kDa correspond to the N-terminal region of the after different chase periods in non-reducing and reducing conditions revealed that VEGF-C is first synthesized as a secreted VEGF-C after cleavage of the signal peptide between Ala31 and Phe32 ( Figure 3 , arrowhead on the 58 kDa precursor, most of which undergoes dimerization before secretion into the culture medium (Figure 2A , left). The 29 kDa form then represents the C-terminal half of the VEGF-C precursor generated by cleavage between upper panels, arrows '58' and '58ϫ2' in lanes 0-45Ј). It is cleaved further, forming a 29 and a 31 kDa polypeptide Arg227 and Ser228 (arrowhead on the right). This polypeptide contains one putative N-linked glycosylation site and (lanes 0-2 h, arrows 29/31), and rapidly secreted, as only a trace amount of the labelled protein was found may be cleaved additionally at its C-terminus, as we could not isolate VEGF-C either by using an antiserum against intracellularly after a 2-6 h chase period. Most of the secreted VEGF-C was made of disulfide-linked low the C-terminal amino acid residues 372-394 or by using the 6ϫHis tag at its C-terminus (data not shown). The molecular weight forms at all time points analysed ( Figure  2A , lower panels), indicating that proteolytic processing 21 kDa form is generated by cleavage of the VEGF-C precursor between Ala111 and Ala112 (grey arrowhead). accompanies the secretion of VEGF-C. Proteolytic cleavage was detected in cell lysates at 0 min and in the media This cleavage of the recombinant protein thus occurs nine residues C-terminal of the cleavage site located between after a 15 min chase period, but the resulting chains of 31 and 29 kDa were held together by disulfide bonding Arg102 and Thr103, originally described in cultures of PC-3 cells . Mature polypeptides of improve separation of the 29 and 31 kDa components of the doublet (data not shown). 21 and 31 kDa thus contain the entire VEGF homology domain with all eight conserved cysteine residues and two putative N-glycosylation sites.
VEGF-C is processed similarly in different cell types
Taking into account these results and analysis of VEGF-C composition in reducing and non-reducing conditions, To exclude the possibility that the observed VEGF-C processing pattern is cell type specific and/or occurs only one can conclude that the main fraction of processed VEGF-C consists of disulfide-bonded N-and C-terminal in cells expressing extremely high VEGF-C levels, we analysed VEGF-C isolated from different transfected and parts of VEGF-C precursor cleaved between Arg227 and Ser228 (bands 1-3 in Figure 2A and B). Migration of the non-transfected cells using the 882 antiserum. The main form of both endogenous VEGF-C, produced by PC-3 proteins in non-reducing conditions suggests that the proteolytic processing occurs gradually. Band 1 presumcells or HT1080 cells, and of the recombinant VEGF-C expressed in 293-EBNA, COS-7 and HT1080 cells is a ably contains tetrameric complexes made of two 29/31 kDa dimers linked by disulfide bonds ( Figure 2B ). Analysis doublet of 29/31 kDa. The 15, 21 and 58 kDa VEGF-C forms produced by PC-3 and 293-EBNA cells also had of band 2 suggests that it contains trimers made of the 29/31 kDa dimer disulfide-bonded with the 21 kDa form. similar mobilities in SDS-PAGE. The proteolytic processing of the VEGF-C precursor in COS cells was less It also includes small amounts of 43 and 58 kDa polypeptides. However, the major fraction of the 29 and 31 kDa efficient when compared with other cell types, possibly due to a high level of expression or a species difference polypeptides migrates in SDS-PAGE as a disulfide-bonded heterodimer (band 3, compare with bands 1 and 2), while (data not shown). Taken together, these results indicate that VEGF-C is processed similarly in different cell types. most of the 21 kDa form migrates as a monomer (band 6). Some non-processed monomeric 58 kDa precursor and
We further analysed whether the 21 kDa VEGF-C form could be produced by proteolytic cleavage of the 31 kDa partially processed 43 kDa polypeptide are also included in band 3. Band 4 is formed mainly by the C-terminal form. Serum-free CM was collected from PC-3 cell cultures after various periods, concentrated and analysed half of the VEGF-C precursor (29 kDa), linked by disulfide bonds with its N-terminal fragment of 15 kDa, and band 5 by Western blotting using the antiserum 882. As can be seen from Figure 4A , the 21 kDa form accumulated in contains the monomeric N-terminal half of the precursor and a small fraction of the 15 and 21 kDa forms heterodithe medium during cell culturing. A similar product could not be detected in 293-EBNA cells, because cleavage of merized by disulfide bonds. An identical processing pattern was observed when R102S VEGF-C was analysed to VEGF-C in these cells occurs more C-terminally (see to bind to and stimulate tyrosine phosphorylation of VEGFR-3 and VEGFR-2 expressed in porcine aortic endothelial (PAE) cells (Pajusola et al., 1994; Waltenberger et al., 1994) . Non-transfected PAE cells did not show significant binding of radioiodinated purified ∆N∆C, while specific high affinity binding sites were detected in PAE/ VEGFR-3 and PAE/VEGFR-2 cells ( Figure 5 ). The affinities were 135 and 410 pM, respectively, based on Scatchard analysis of the binding data ( Figure 5A and B). VEGF-C and VEGF competed with each other for VEGFR-2 binding, VEGF being more efficient in this respect, indicating that the binding involves overlapping sites of the receptor ( Figure 5C and D). ∆N∆C, like VEGF, could also be cross-linked to VEGFR-2 on PAE cells ( Figure 5F ) and it bound to soluble extracellular domains VEGFR-3 and VEGFR-2 in a dose-dependent fashion at concentrations of 0.2-20 nM ( Figure 5G and H and data not shown). This effect was not affected by the presence Figure 3 ) and thus deletes about half of the peptide sequence recognized by the antiserum. However, the of the 6ϫHis tag (data not shown). The stimulation of VEGFR-2 was comparable with that of similar concentraremaining epitope appears to be sufficient for immunoprecipitation of the 21 kDa form using the same antiserum tions of VEGF. Heparin at 1 µg/ml either did not affect or even decreased binding of ∆N∆C by both receptors (Figures 1-3 and 4B) . Addition of concentrated CM from PC-3 cells to medium containing 35 S-labelled recombinant (data not shown). Altogether, these data indicate that the proteolytically processed 21 kDa VEGF-C is a ligand and VEGF-C also caused its proteolytic cleavage, with accumulation of the 21, 43 and 15 kDa products ( Figure 4B , an activator of both VEGFR-3 and VEGFR-2. arrows), indicating that the protease responsible for VEGF-C cleavage is secreted to the medium. We also observed
Mature VEGF-C has VEGF-like activities
The ability of ∆N∆C to activate VEGFR-2 raised the proteolytic cleavage of the recombinant 31 kDa VEGF-C polypeptide accompanied by simultaneous accumulation question of whether it can also induce biological responses characteristic of VEGF. We found that ∆N∆C stimulated of the 21 kDa form upon long-term storage of the CM from transfected 293-EBNA cells (data not shown).
the proliferation of bovine capillary endothelial (BCE) cells, although equal stimulation required~50-fold higher concentrations of VEGF-C in comparison with VEGF 'Recombinantly processed' VEGF-C binds VEGFR-3 and VEGFR-2 with high affinity and induces ( Figure 6A ). ∆N∆C, like wt VEGF-C, stimulated the migration of BCE cells in collagen gel, again at higher receptor autophosphorylation In order to identify and analyse biologically active VEGFconcentrations when compared with VEGF ( Figure 6B ). Also, pure recombinant ∆VEGF-C injected subcutaneously C polypeptides, we generated a panel of deletion mutants of VEGF-C based on the proteolytic processing sites into guinea pig skin increased the permeability of blood vessels in a dose-dependent manner ( Figure 7A ). In this (Figure 3 ). We found that the ability to stimulate tyrosine phosphorylation of VEGFR-3 and VEGFR-2 depends assay, only 4-to 5-fold higher concentrations of ∆N∆C were required compared with VEGF ( Figure 7B ). Altoon the presence of the VEGF homology domain. This conclusion is based on the activating properties of polypepgether, these data indicate that the proteolytic processing of the VEGF-C precursor generates a biologically active tides encoded by the constructs VEGF-C wt, N-His, NT, ∆N, and ∆N∆C, schematically presented in Figure 3 (data factor which possesses VEGF-like effects on endothelial cells, stimulating their proliferation and migration, as well not shown). The construct CT, in which the signal sequence was fused to Ser228 of the C-terminal cleavage site, was as the permeability of blood vessels in vivo. expressed efficiently and secreted to the culture medium, but it did not stimulate tyrosine phosphorylation of Proteolytic maturation affects receptor specificity and activity of VEGF-C VEGFR-2 or VEGFR-3 (data not shown). The maximal receptor-stimulating activity corresponded to the 21 kDa
We next addressed the question of whether proteolytic processing affects the ability of VEGF-C to bind and to form, in which both the N-and C-terminal propeptides were deleted at the proteolytic processing sites or in their activate VEGFR-3 and VEGFR-2. In addition to the above-described ∆N∆C, we also generated the VEGF-C close proximity (construct ∆N∆C) (see below).
We next produced the ∆N∆C protein in the Pichia R226,227S form in which Arg226 and Arg227, adjacent to the cleavage site, were replaced with serine residues pastoris yeast expression system and analysed its ability ( Figure 3) . As a consequence, the proteolytic processing being an analogue of fully processed, mature VEGF-C ( Figure 8A , lanes 3 and 4). at this site was almost completely abolished, as detected by Western blotting using the 882 antiserum ( Figure 8A , As can be seen from Figure 8B , all processed VEGF-C forms bind to R-3EC, with preferential binding of the lane 2). Small amounts of the 31 and 21 kDa polypeptides were, however, found in [ 35 S]R226,227S immunoprecipi-21 kDa form (lanes 2, 5, 7 and 13). Even more striking was the selective binding of the mature 21 kDa form of tates, possibly due to clevage at an alternative site ( Figure  9B , lane 1). R226,227S can thus be considered an analogue wt VEGF-C and of ∆N∆C by the VEGFR-2 extracellular domain-alkaline phosphatase fusion protein (R-2EC, lanes of the VEGF-C precursor, while wt VEGF-C consists mostly of partially processed 29 and 31 kDa forms, ∆N∆C 3, 6, 8 and 14) . Neither protein A-Sepharose (see Figure Fig ∆N∆CϾwtϾR226,227S, i.e. enhanced binding was obtained upon inclusion of the more mature forms. Recombinant VEGF165 failed to displace VEGF-C from VEGFR-3, but VEGF, ∆N∆C and wt VEGF-C efficiently displaced labelled VEGF-C from VEGFR-2, ∆N∆C being more potent in comparison with wt VEGF-C ( Figure 8D ). The non-processed R226,227S form showed only weak competition with [ 125 I]VEGF-C∆N∆C, which could be attributed either to its much lower affinity for VEGFR-2, or to the presence of a small amount of the mature forms, cleaved at an alternative site (see above). and with the degree of proteolytic processing ( Figure 8E ). ∆N∆C showed a higher activity than wt VEGF-C (lanes 1, lane 1) nor protein G-Sepharose alone, or in combination 3 and 4), and R226,227S had a considerably weaker effect with the anti-alkaline phosphatase antibodies (lanes 10 on autophosphorylation of VEGFR-3, and almost no effect and 11), bound the 21 kDa form, although very small on VEGFR-2 autophosphorylation (lane 2). Finally, the amounts of the the 58 and 31 kDa VEGF-C forms were ability of different VEGF-C forms to promote vascular bound unspecifically (lanes 8, 9 and data not shown). The permeability was examined in the Miles assay. CM conspecificity of VEGF-C binding was supported by the taining the VEGF-C polypeptides were pre-treated with finding that R-2EC bound VEGF, but not PlGF, while monoclonal anti-VEGF neutralizing antibodies to elimin-R-3EC did not bind VEGF (data not shown).
ate the effect of endogenous VEGF produced by 293-Analysis of the receptor-bound material in non-reducing EBNA cells. Although the effect of pure VEGF was conditions revealed that the 60 kDa polypeptide, which neutralized in control experiments, the antibody-treated was bound preferentially to R-3EC consisted of disulfide-CM still slightly increased vascular permeability, presumbonded 29 and 31 kDa heterodimers (lane 13, upper ably due to the presence of other permeability factors arrow). Most of the 21 kDa polypeptide bound to both ( Figure 8F and data not shown). CM containing wt and R-3EC and R-2EC migrated as a monomer in these ∆N∆C VEGF-C increased vascular permeability, while conditions (lanes 13 and 14, lower arrow). This finding the effect of R226,227S CM did not differ significantly was most surprising with regard to previously published from that of CM from mock-transfected cells ( Figure 8F ). data concerning other VEGF family members (Maglione Importantly, identical dilutions of CM were used for these et Heldin et al., 1993; Olofsson et al., 1996a;  experiments and for the experiments presented in Figure  Ferrara , 1997).
8C-E. A Western blot analysis of CM using anti-VEGFWe next analysed the ability of the described VEGF-C C antiserum 882 is shown in Figure 8A to illustrate the forms to compete with [ 125 I]VEGF-C(∆N∆C) for binding relative amounts of the factors present. to VEGFR-2 and VEGFR-3. As can be seen from Figure precipitation was carried out to better estimate the relative processed VEGF-C exists mainly as a monomer or a non-disulfide-bonded dimer, which binds VEGFR-3 and amounts of each processed form ( Figure 9B, lanes 1, 3  and 5 ). In the experiment presented in Figures 8 and 9 , VEGFR-2. We were interested in the possibility that dimerization of the processed VEGF-C occurs via nonthe amount of the 21 kDa polypeptide was approximately one-third of that of the 31 kDa form in the same wt covalent interactions. Unlike VEGF, which migrates in non-reducing conditions as a dimeric protein of~44 kDa, VEGF-C conditioned medium. Taken together, these data indicate that the ability to bind to and to activate VEGFRmost of ∆N∆C migrates as a monomer ( Figure 9A ). As can be seen from Figure 9B , lanes 6 and 8, about one-3 and VEGFR-2 increases during the proteolytic processing of VEGF-C. Non-processed VEGF-C preferenhalf of disuccinimidyl suberate (DSS)-cross-linked VEGF and ∆N∆C migrated as dimers (arrows pointing to lanes tially binds to and activates VEGFR-3, while the mature 21 kDa VEGF-C form is a high affinity ligand and an 6 and 8 on the right) in reducing conditions. Taking into account that in our conditions~90% of VEGF migrated activator of both VEGFR-3 and VEGFR-2.
as a disulfide-bonded dimer ( Figure 9A , lane 1), we conclude that mammalian cells produce ∆N∆C preferen-
Mature form of VEGF-C consists of non-covalent dimers
tially as a non-covalently bonded dimer ( Figure 9A , lane 2 and Figure 9B , lanes 5 and 6). When wt VEGF-C Members of the PDGF/VEGF family are active only as dimers. However, as shown above, the proteolytically was cross-linked, the amount of the 21 kDa form was are subject to cleavage; and (iii) a variety of processed forms are secreted. On the other hand, there are several important differences between PDGF-BB and VEGF-C, concerning both their processing and the structure of the mature growth factors. VEGF-C is released rapidly from cells upon secretion. Upon biosynthesis, two VEGF-C polypeptides, oriented in an anti-parellel fashion, form a dimer linked by disulfide bonds and apparently also by non-covalent bonds. Antiparallel dimerization is supported by the disulfide bonding of the N-and C-terminal halves (29/31 kDa doublet) of the precursor. Precursor homodimerization is thus followed the cell lysates. Most of the secreted VEGF-C is then already cleaved between Arg227 and Ser228, and the resulting polypeptides initially form a tetramer, originating considerably decreased ( Figure 9B , lane 4), suggesting that it is bound to other polypeptides. Also, additional from two precursor polypeptides bound to each other. This processing step is probably conserved in evolution, bands of 60, 80 and 120 kDa appeared in reducing conditions (lane 4, arrows on the left). The first of these because the human, mouse and avian VEGF-Cs, as well as FIGF, contain the same amino acid sequence, SIIRRS, apparently represents heterodimers of 29 and 31 kDa forms; the 80 kDa complex is most probably a trimer, surrounding the cleavage site, and a doublet of polypeptides of~30 kDa is detected in the corresponding immunoconsisting of 21, 29 and 31 kDa polypeptides, and the 120 kDa band contains two dimerized VEGF-C precursors, precipitates from the CM of transfected cells Kukk et al., 1996; Orlandini et al., 1996) . most of which are cleaved at the 227R/228S site. When cleavage between Arg227 and Ser228 was abolished (the Morover, most of the VEGF-C secreted by different cell types migrates in reducing conditions as a doublet of 29/ R226,227S mutant), no cross-linked complexes of 60 and 80 kDa were detected; instead complexes of~120 kDa 31 kDa (data not shown). The efficient secretion of the R226,227S mutant as well were very prominent, both in non-reducing conditions (data not shown) and upon cross-linking (lane 2). These as the presence of small amounts of unprocessed wt VEGF-C precursor in the CM indicate that the intracellular complexes presumably consist of non-processed VEGF-C dimers linked by disulfide bonds. Despite the fact that proteolytic cleavage is not a prerequisite for VEGF-C secretion. The C-terminal cleavage of the PDGF-BB we were unable to cross-link the complexes completely, these data, along with the analysis of VEGF-C in reducing precursor occurs in close proximity to the site which corresponds to Arg227 in VEGF-C. Cleavage of high and non-reducing conditions, clearly show the co-existence of a variety of its di-and multimeric forms, assembled molecular weight VEGF forms by plasmin, with release of diffusible VEGF, also takes place only 10 amino acid via disulfide bonding and non-covalent interactions. We also found that recombinant N-and C-termini of VEGFresidues N-terminal of the VEGF-C cleavage site when VEGF and VEGF-C sequences are aligned (Houck et al., C were able to form heterodimers when co-expressed in mammalian cells (data not shown), emphasizing the 1992; Keyt et al., 1996a) . The proteases responsible for the cleavage of these growth factors might differ, however, existence of a mechanism for the formation of such dimers in mammalian cells. because of differences in peptide sequences surrounding the cleavage sites (Ö stman et al., 1988) . The next step of the proteolytic processing of VEGFDiscussion C, which removes the N-terminal propeptide, occurs extracellularly, because the 21 kDa polypeptide was not Proteolytic processing of VEGF-C Based on the described results, we propose the VEGF-C detected in cell lysates. This differs from the proteolytic processing of PDGF, which occurs exclusively intracellulproteolytic processing model, which is presented schematically in Figure 10 . This model resembles the model for arly (Ö stman et al., 1992) . The 21 kDa form accumulated even upon incubation of cell-free CM, indicating that the the proteolytic processing of PDGF, especially of PDGF-BB (Ö stman et al., 1988, 1992) T103, respectively) suggest that such proteases are either made by transfected overexpressing cells is a non-covalent dimer. Most of the mature VEGF-C and ∆N∆C migrate redundant or that cell type-specific factors determine the exact cleavage sites. This stage of the proteolytic proat 21 kDa in reducing and non-reducing conditions. Despite this, similar proportions of dimeric molecules (~50%) are cessing occurs in a more gradual fashion, and it finally gives rise to mature VEGF-C, composed of two VEGF detected upon cross-linking the recombinantly produced VEGF and ∆N∆C. Of the various forms, these have the homology domains bound by non-covalent interactions.
The small amounts of the shortest identified VEGF-C highest affinity for VEGFR-3 and VEGFR-2. The tetraand trimeric VEGF-C molecules, which were detected polypeptide of 15 kDa represent the N-terminal part of the precursor, which binds via disulfide bond(s) with the upon cross-linking, presumably involve both disulfide bonds connecting the N-and C-terminal parts of separate C-terminal 29 kDa propeptide. The mobility of the 15 kDa form in SDS-PAGE and its recognition by both antisera precursor chains and non-covalent interactions between the two VEGF homology domains (see Figure 10 ). Subsequent used in the present study suggest that it contains most of the VEGF homology domain, excluding the first glycosylation removal of the N-terminal propeptide from both precursors would then explain the formation of the non-disulfidesite, indicating the existence of an additional proteolytic processing site. Interestingly, this form is very similar to linked mature VEGF-C dimer. Absense of interchain disulfide bonds is unusual for the the short splicing variant (clone vh 1.1), reported for VRP (Lee et al., 1996) , and thus it may have an analogous, so members of the PDGF/VEGF family, in which the second and fourth cysteine residues are involved in anti-parallel far unknown function. It is possible that the 15 kDa polypeptide interacts with the 21 kDa form, giving rise to interchain disulfide bonds (Andersson et al., 1992; Pötgens et al., 1994) . These disulfide bonds are crucial for dimeriza trimer. It might have an antagonistic activity, competing with the mature ligand for receptors. Small amounts of a ation and biological activity of VEGF, but are not required for dimerization or mitogenic effects of PDGF-BB secreted 43 kDa form were also detected, but we could not isolate enough of this form to determine its peptide (Andersson et al., 1992; Kenney et al., 1994; Pötgens et al., 1994) . It has also been shown that the dimer sequence. However, the inability of both VEGF-C antisera to precipitate this form upon reduction/alkylation of disulinterface in PDGF-BB is sufficient to stabilize the dimer substantially in the absence of a covalent linkage (Oefner fide bonds and the correlation of its appearence with the appearance of the 15 kDa form suggest that it might et al., 1992) . It is possible that such an interaction of the mature polypeptide chains is tighter in VEGF-C than in represent the complementary C-terminal part of the VEGF-C precursor after cleavage of the 15 kDa N-terminal part.
PDGF-BB. Interestingly, the mature VEGF-C contains an extra cysteine residue at position 137, located between Several lines of evidence indicate that mature VEGF-C the first and the second cysteine residue characteristic of essential for the development of haematopoietic/endothelial cells will need further studies. the PDGF/VEGF family. This residue is also conserved in mouse and avian VEGF-C A.Eichmann et al., unpublished data) and in FIGF (Orlandini et al., Significance of the proteolytic processing of 1996). This residue remains unpaired after cleavage of the
VEGF-C N-terminal propeptide, which contains another unpaired
Our results demonstrate that during proteolytic processing, cysteine residue.
VEGF-C acquires the ability to bind to and to activate VEGFR-2, and increases its affinity and activating properties towards VEGFR-3. Many other cytokines and growth
Properties of the mature VEGF-C
The results with ∆N∆C, which mimics mature VEGF-C, factors are also synthesized initially as precursors. These include members of the epidermal growth factor (EGF) support our earlier observations Kukk et al., 1996) and clearly indicate that proteolytically family, and the transforming growth β (TGF-β) superfamily, interleukins 1α and 1β, nerve growth factor, processed VEGF-C binds to and activates both VEGFR-3 and VEGFR-2. A single class of high affinity sites was hepatocyte growth factor (HGF) and others. Proteolytic processing of TGF-β and HGF precursors is an essential observed in PAE/VEGFR-3 cells (K D ϭ 135 pM) and PAE/VEGFR-2 cells (K D ϭ 410 pM). These values are step in the formation of the biologically active ligands (Naka et al., 1992; Vigna et al., 1994; Dubois et al. , of similar magnitude to the affinities reported for the VEGF-VEGFR-2 interaction (Terman et al., 1992; . Our data indicate that the proteolytic processing of VEGF-C plays a similar role, endowing the mature Waltenberger et al., 1994) . VEGF-C and VEGF displace each other from VEGFR-2, indicating that the same region polypeptide with the ability to activate VEGFR-2. Taking into account the presence of VEGFR-2 in many types of of this receptor is involved in binding of both ligands. Surprisingly, none of the three basic residues reported to endothelia and the broad expression pattern of VEGF-C, we propose that the biosynthesis of VEGF-C as a precursor be critical for VEGFR-2 binding by VEGF (Keyt et al., 1996b) are conserved in VEGF-C, indicating that other prevents unnecessary angiogenic effects, elicited via VEGFR-2, and allows VEGF-C to signal preferentially residues of VEGF-C are important for its interaction with VEGFR-2. VEGF-C also dose-dependently stimulated via VEGFR-3, which is restricted to the venous endothelia during early stages of development and to the lymphatic autophosphorylation of VEGFR-3 and VEGFR-2 but, in agreement with previously reported data (Lee et al., 1996) , endothelium during later stages. In certain circumstances, proteolytic processing would release mature VEGF-C, we could not detect binding of VEGF-C to VEGFR-1.
Like VEGF, VEGF-C stimulates the proliferation and which is able to signal via both VEGFR-3 and VEGFR-2. It is also possible that activation of both VEGFR-3 and migration of endothelial cells and increases vascular permeability, albeit at concentrations higher than required VEGFR-2, either as homo-or as heterodimers, is necessary to elicit a complete biological response to VEGF-C. In for VEGF. These activities are probably mediated through VEGFR-2 activation (Park et al., 1994; this case, proteolytic processing might provide a regulatory mechanism which gives the possibility of fine tuning the et al., 1994). Higher effective concentrations of VEGF-C may depend on its lower affinity for VEGFR-2, and on biological functions of VEGF-C. Also, the extracellular processing step introduces an additional level of regulation its inability to bind VEGFR-1, precluding the formation of VEGFR-1-VEGFR-2 heterodimers, which may be of the VEGF-C activity. An important function of the proteolytic processing of required for maximal biological responses to VEGF (Waltenberger et al., 1994; DiSalvo, 1995; Cao et al., PDGF, and possibly also of certain VEGF isoforms, is to control the bioavailability of the growth factor by removal 1996; Clauss et al., 1996) . The role of VEGFR-2 in the effects of VEGF-C in vivo remains to be studied.
of the C-terminal propeptide, containing a short stretch of positively charged amino acid residues responsible for the The paracrine relationship between the VEGF-C and VEGFR-3 expression patterns in embryos suggests that retention of the molecule at the cell surface or in the pericellular matrix (La Rochelle et al., 1991; Houck et al. , VEGF-C functions in the formation of the venous and lymphatic vascular systems, where VEGFR-3 is expressed 1992; Keyt et al., 1996a) . The resulting effect is similar to that of alternative splicing, which generates polypeptide Kukk et al., 1996) . Our unpublished observations from transgenic mice support such a variants devoid of the retention domain. VEGF-C is secreted readily into the CM, independently of whether it notion (Jeltsch et al., 1997) . However, the redundancy of VEGF-C with VEGF in VEGFR-2-mediated signalling is processed or not. The isolated C-terminal half of VEGF-C is also released efficiently into the CM, when provided might account for the interesting observations that VEGF -/-mice have delayed endothelial cell differentiwith the VEGF-C signal sequence. In addition, VEGF-C does not bind to heparin, which is known to interact with ation, while in VEGFR-2 -/-mice both haematopoietic and endothelial cell development is aborted, suggesting the basic regions of the long VEGF splice isoforms. The short stretch of basic amino acids, located at the Cthat (a) VEGFR-2 ligand(s) distinct from VEGF (such as VEGF-C) might play an important role in these processes terminus of the VEGF-C precursor (residues 372-386), either does not affect its secretion or is proteolytically (Shalaby et al., 1995; Carmeliet et al., 1996; Ferrara et al., 1996) . Indeed, VEGF-C expression is first detected in day removed. These data suggest that the bioavailability of VEGF-C is not regulated by the same mechanism as in 7 p.c. embryos , which is striking, considering the first appearance of the VEGFR-3 mRNA the case of PDGF and VEGF. The propeptides also do not seem to be essential for the folding, assembly or on day 8.5 of gestation . The question of whether VEGF-C is indeed another factor secretion of VEGF-C homodimers, as the ∆N∆C form
Generation of VEGF-C antisera
was secreted efficiently as a dimer, and possessed all the Antisera 882 and 905 were generated by immunization of rabbits tested activities of naturally processed VEGF-C.
with synthetic peptides, corresponding to residues 104-120 (NH 2 -
The major secreted VEGF-C form contains the C- et al., 1988) . This observation, ting followed previously published procedures .
together with increasing evidence that the binding of
Immunoprecipitations of metabolically 35 S-labelled VEGF and VEGFgrowth factors to the extracellular matrix is a major C from CM were carried out using mouse monoclonal anti-human VEGF neutralizing antibody (R&D Systems) and antiserum 882 or 905, mechanism regulating growth factor activity (Taipale and respectively. VEGF and VEGF-C bound to antibodies were precipitated Keski-Oja, 1997) , suggests that the secreted VEGF-C, using protein G-Sepharose (Pharmacia) and protein A-Sepharose respectwhich is proteolytically cleaved at the R227/S228 site, tion of the BR3 motifs, which differ from previously
Generation of VEGF-C mutants
known repeated motifs in secreted proteins of vertebrata, VEGF-C mutants were generated using the Altered Sites II in vitro might provide additional specificity to the VEGF-C associMutagenesis System (Promega). For this purpose, the BamHI fragment ation with the extracellular matrix ( Figure 10 ). Cleavage of the VEGF-C cDNA from VEGF-C/pREP7 was subcloned in antisense orientation into the pALTER-1 vector. To generate of the N-terminal propeptide would then release the active the VEGF-C point mutants, suitable oligonucleotides were synthesized VEGF-C not only from the latent state, but also from its and the mutagenesis procedure was carried out according to the manufacassociation with the extracellular matrix ( Figure 10 ). In turer's instructions. To generate the N-His construct, an 84mer oligofact, some similarity can be seen between structural nucleotide was used to introduce the 6ϫHis tag in place of Phe32 (between Ala31 and Glu33). The NT VEGF-C construct was obtained organization of secreted VEGF-C and TGF-β, with the using an oligonucleotide encoding a stop codon instead of Lys214. The N-and C-terminal VEGF-C propeptides being functional deletion mutants were produced by using a loop-out deletion strategy, homologues of the TGF-β latency-associated protein and as described in (Bergman et al., 1995) . A 65mer oligonucleotide was the latent TGF-β-binding protein respectively. The latter used to generate the ∆N VEGF-C construct, in which residues 32-102 has a domain structure and is similar to fibrillin (reviewed of VEGF-C were deleted. In the second round mutagenesis procedure, ∆N VEGF-C and a 52mer oligonucleotide were used to introduce the in Miyazono et al., 1994; Taipale and Keski-Oja, 1997 ).
6ϫHis tag followed by a stop codon and a NotI site immediately after
The questions of whether secreted VEGF-C indeed remains
Ile225 to generate ∆N∆C. The CT construct was generated on the basis associated with the extracellular matrix and which protease of the N-His construct. Oligonucleotides (54 and 63mer) were used to is responsible for the proteolytic processing of VEGF-C introduce NcoI sites in the same reading frame, one at the 3Ј end of the 6ϫHis tag, and another one at the 5Ј end of the sequence encoding the remain to be answered in the future.
C-terminal part of VEGF-C (starting from Ser228). The resulting construct was subjected to NcoI digestion and ligation, giving rise to the construct encoding VEGF-C signal peptide followed by the 6ϫHis
Materials and methods
tag and the C-terminal half of VEGF-C (additional proline and tryptophan residues were present between the 6ϫHis tag and the C-terminus as a Cell culture, transfections and metabolic labelling result of introduction of the NcoI site in the same reading frame). The 293-EBNA cells, COS-7 cells, and HT1080 cells were cultured in mutant constructs in the pALTER vector were digested with HindIII and Dulbecco's modified Eagle's medium (DMEM)-10% fetal calf serum NotI, subcloned into HindIII-NotI-digested pREP7 and used to transfect (FCS); PC-3 cells in Ham's F12 medium-7% FCS; PAE-KDR, PAE-293-EBNA cells. Flt1 (Waltenberger et al., 1994) and PAE-Flt4 (Pajusola et al., 1994) Strain GS115 of the yeast P.pastoris and the expression vector pIC9 cells in Ham's F12 medium-10% FCS. BCE cells (Folkman et al., 1979) (Invitrogen) were used according to the manufacturer's instructions to were cultured as described in Pertovaara et al. (1994) . Cell transfections express ∆N∆C. The VEGF-C sequence was amplified by PCR with a were carried out using the calcium phosphate precipitation method. An sense primer encoding residues 103-108 and an antisense primer equivalent amount of the pREP7 plasmid without insert was used in encoding residues 212-215, followed by a 6ϫHis tag. EcoRI sites were mock transfections. When used for stimulation experiments, and for introduced in the the 5Ј and 3Ј termini of the sense and antisense primers. detection of VEGF-C expression by Western blotting, the culture medium
The amplified fragment was fused in-frame to the yeast a-factor signal was changed to DMEM-0.1% bovine serum albumin (BSA) 48 h after sequence in pIC9. transfection and, after an additional 48 h, this medium was collected, clarified by centrufugation, concentrated using Centriprep-10 or CentPurification and N-terminal sequence analysis of VEGF-C ricon-10 devices (Amicon) and used in the experiments. Metabolic Antibody 882 was employed to purify wt VEGF-C from 1.2 l of CM of labelling of non-transfected cells and cells transfected with VEGF-C transfected 293-EBNA cells by immunoaffinity chromatography. The IgG constructs was carried out by addition of 200 and 100 µCi/ml respectively fraction isolated using protein A-Sepharose (Pharmacia) was covalently of Pro-mix™ L-[ 35 S] in vitro cell labelling mix (Amersham) to the bound to CNBr-activated Sepharose CL-4B (Pharmacia) at a concentraculture medium devoid of cysteine and methionine. After 4 h, the tion of 5 mg of IgG/ml Sepharose resin (Harlow and Lane, 1988) . medium was collected or, in some experiments, replaced with DMEM-N-His VEGF-C was isolated using Talon™ Metal Affinity Resin (Clon-0.1% BSA, and after an additional incubation for 4 h the media were tech). Yeast ∆N∆C VEGF-C was purified using Ni-NTA Superflow resin combined, cleared by centrifugation and used for the immunoprecipi- (QIAGEN) . No contaminating proteins were detected when 2 µg of the yeast purified ∆N∆C was analysed by SDS-PAGE with subsequent tations.
Coomassie R-250 or silver staining of the gel. The purified material was of isotonic saline. The analysed polypeptides were dissolved in PBS and injected intradermally in a volume of 0.1 ml into the back of guinea analysed by electrophoresis, Western blotting and N-terminal amino acid sequence analysis as described earlier . An additional pigs. In some experiments, the analysed material was pre-treated with 15 µg/ml of anti-human VEGF neutralizing antibody (R&D systems). sequence obtained during the analysis of the 29-30 kDa polypeptide, NH 2 -AVVMTQTPAS-COOH, corresponded to the variable region of the After 20 min, the animals were sacrificed under anaesthesia, skin at the injection sites was excised and the amount of extravasated dye was Ig-κ chain, which was present in the purified material due to leakage from the affinity matrix.
quantitated by elution of the dye with 4.0 ml of formamide for 4 days at 45°C and measuring the optical density of the eluate at 620 nm (Udaka et al., 1970) . Similar results were obtained in three separate Pulse-chase and dimerization studies Metabolic labelling, immunoprecipitation and pulse-chase analysis of experiments. polypeptides were done essentially as described previously . To study the composition of the VEGF-C dimers, the labelled polypeptide bands electrophoresed under non-reducing conditions were
